Therapeutic effect comparison of Tiji'ao or gemcitabine combined with nedaplatin and concurrent three-dimensional conformal radiotherapy for stage III non-small cell lung cancer
10.3760/cma.j.issn.1008-6315.2016.08.010
- VernacularTitle:替吉奥及吉西他滨分别联合奈达铂同步三维适形放射治疗Ⅲ期非小细胞肺癌的效果比较
- Author:
Jinguang HE
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Concurrent chemoradiotherapy;
Tiji'ao;
Gemcitabine;
Nedaplatin
- From:
Clinical Medicine of China
2016;32(8):704-708
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the therapeutic effect of Tiji'ao or gemcitabine combined with nedaplatin and concurrent three?dimensional conformal radiotherapy in the treatment of stage III non?small cell lung cancer( NSCLC)?Methods A total of 92 patients with stage III NSCLC who were treated in the Heze Municipal Hospital from January 2013 to September 2015 were selected,and according to the envelope method were randomly divided into Tiji'ao + nedaplatin + three?dimensional conformal radiotherapy( S?1 + NDP + 3D?CRT) group ( Observation group, n = 46 ) and gemcitabine + nedaplatin + three?dimensional conformal radiotherapy(GEM+NDP+3D?CRT) group(Control group,n=46)?Rradiotherapy and chemotherapy trearment were performed concurrent,the short?term curative effect,the improvement of the quality of life and the safety of the two groups were compared?Results Six months after treatment,the curative efficiency( RR) of Observation group and Control group was 76?09%(35/46) and 78?26%(36/45) respectively,clinical benefit rate(DCR) was 95?65%( 44/46 ) and 93?48%( 43/46 ) respectively, there were no statistically significant differences between two groups( X2=0?062,0?517,P>0?05)?There was no significant difference between RR of squamous cell carcinoma and adenocarcinoma in Observation group( 77?78%( 21/27) vs?73?68%( 14/19) ,χ2=0?103,P>0?05) ,and there was no significant difference between RR of squamous cell carcinoma and adenocarcinoma in Control group( 80?00%( 20/25) vs?76?19%( 16/21) ,χ2=0?097,P>0?05)?There was no significant difference between Observation and Control groups in term of clinical improvement rate( 63?04%( 29/46) vs?56?52%( 26/46),χ2=0?489,P>0?05)?There were no significant differences between Observation and Control groups in terms of incidence of Gastrointestinal reactions,RP and esophagitis(86?96%(40/46) vs?78?26%(36/46), 84?78%(39/46) vs?91?3% ( 42/46), 86?96%( 40/46) vs?86?96%( 40/46);χ2 = 3?95, 4?35, 0?34;P>0?05);but in terms of bone marrow suppression, reduction in incidence of white blood cells ( WBC ) , thrombocytopenia in Observation group were 80?43%( 37/46 ) , 69?57%( 32/46 ) , in the control group were 91?3%( 42/46) , 93?48% ( 43/46 ) , there were significant differences between the two groups (χ2 =10?43, 19?37,P<0?05 )?Conclusion For stage Ⅲ non?small cell lung cancer combined with platinum?based chemotherapy concurrent three?dimensional conformal radiotherapy, Tiji'ao and gemcitabine have equivalent efficacy,but Tiji'ao has mild side effects,easy to oral absorption,easy to elderly patients with tolerance?But long?term efficacy remains to be further follow?up
